Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 291

Sort by

Sort Order Select

Journal Articles

Outcomes of hypomethylating agent failure in patients with myelodysplastic syndromes

Blood (2025) 146 (Supplement 1): 2075.

https://doi.org/10.1182/blood-2025-2075

Published: 2025

Journal Articles

Characteristics, genomic landscape, and prognostic impact of trisomy 8 on contemporary outcomes in patients with newly diagnosed Acute Myeloid Leukemia (AML)

Blood (2025) 146 (Supplement 1): 1726.

https://doi.org/10.1182/blood-2025-1726

Published: 2025

Journal Articles

Impact of NPM1 co-mutation on outcomes in RAS-mutated Acute Myeloid Leukemia

Fnu Amritpal Singh, Alex Bataller, Alexandre Bazinet, Gautam Borthakur, Courtney DiNardo, Naval Daver, Guillermo Montalban-Bravo, Nicholas Short, Wei-Ying Jen, Ghayas Issa, Hussein Abbas, Sanam Loghavi, Guillermo Garcia-Manero, Farhad Ravandi, Hagop Kantarjian, Tapan Kadia

Blood (2025) 146 (Supplement 1): 7029.

https://doi.org/10.1182/blood-2025-7029

Published: 2025

Journal Articles

Prognostic and therapeutic impact of FLT3 mutations and allelic burden in myelodysplastic syndromes and chronic myelomonocytic leukemia: Results from a multicenter cohort study

Blood (2025) 146 (Supplement 1): 2085.

https://doi.org/10.1182/blood-2025-2085

Published: 2025

Journal Articles

Clinical and biological correlates of blast-transformed chronic myelomonocytic leukemia (CMML): A multicenter study of 493 paired cases at chronic phase and at blast transformation

Blood (2025) 146 (Supplement 1): 2081.

https://doi.org/10.1182/blood-2025-2081

Published: 2025

Journal Articles

Clinical characteristics, demographics, and survival outcomes in newly diagnosed CUX1-mutated Acute Myeloid Leukemia

Michelle Nwachukwu, Farhad Ravandi, Sanam Loghavi, Gautam Borthakur, Tapan Kadia, Courtney DiNardo, Nicholas Short, Elias Jabbour, Guillermo Montalban-Bravo, Alexandre Bazinet, Alex Bataller, Kelly Chien, Danielle Hammond, Mahesh Swaminathan, Wei-Ying Jen, Ian Bouligny, Naval Daver, Guillermo Garcia-Manero, Koji Sasaki

Blood (2025) 146 (Supplement 1): 1620.

https://doi.org/10.1182/blood-2025-1620

Published: 2025

Journal Articles

A Phase II study of azacitidine, venetoclax, and gilteritinib for newly diagnosed adverse risk FLT3-wild type acute myeloid leukemia

Sankalp Arora, Hagop Kantarjian, Manuel Maroun, Gautam Borthakur, Guillermo Garcia-Manero, Guillermo Montalban-Bravo, Ghayas Issa, Kelly Chien, Abhishek Maiti, Maro Ohanian, Mahesh Swaminathan, Wei-Ying Jen, Farhad Ravandi, Hussein Abbas, Nicholas Short

Blood (2025) 146 (Supplement 1): 5226.

https://doi.org/10.1182/blood-2025-5226

Published: 2025

Journal Articles

Clinical outcomes of patients with IDH1/IDH2-mutated clonal hematopoiesis: A single-center retrospective study

Fnu Amritpal Singh, Koji Sasaki, Sanam Loghavi, William D. Marrero, Guillermo Montalban-Bravo, Koichi Takahashi, Hagop Kantarjian, Guillermo Garcia-Manero, Courtney DiNardo, Kelly Chien

Blood (2025) 146 (Supplement 1): 6710.

https://doi.org/10.1182/blood-2025-6710

Published: 2025

Journal Articles

A phase I study of the T-cell receptor-like antibody Hu8F4 in pts with advanced myeloid neoplasms

Blood (2025) 146 (Supplement 1): 1646.

https://doi.org/10.1182/blood-2025-1646

Published: 2025

Journal Articles

Cladribine-based low-intensity therapy is safe and effective in patients with newly diagnosed Acute Myeloid Leukemia (AML) and renal impairment

Caitlin Rausch, Gautam Borthakur, Fadi Haddad, Kelly Chien, Danielle Hammond, Guillermo Montalban-Bravo, Naveen Pemmaraju, Lucia Masarova, Musa Yilmaz, Michael Andreeff, Elias Jabbour, Jan Burger, Nitin Jain, Farhad Ravandi, Tapan Kadia

Blood (2025) 146 (Supplement 1): 3457.

https://doi.org/10.1182/blood-2025-3457

Published: 2025

Journal Articles

Area deprivation index does not influence survival in patients with lower-risk myelodysplastic syndromes at a major cancer center

Mahesh Swaminathan, Alexandre Bazinet, Koji Sasaki, Dan Fox, James Hill, Alex Bataller, Kelly Chien, Guillermo Montalban-Bravo, Danielle Hammond, Michelle Hildebrandt, Ian Bouligny, Wei-Ying Jen, Tapan Kadia, Koichi Takahashi, Courtney DiNardo, Elias Jabbour, Naval Daver, Guillermo Garcia-Manero

Blood (2025) 146 (Supplement 1): 6407.

https://doi.org/10.1182/blood-2025-6407

Published: 2025

Journal Articles

Asciminib for newly diagnosed chronic myeloid leukemia: Results from A phase II trial

Fadi Haddad, Elias Jabbour, Ghayas Issa, Koji Sasaki, Rita Khouri, Alex Bataller, Jayastu Senapati, Tapan Kadia, Guillermo Montalban-Bravo, Naveen Pemmaraju, Anwesha Ray, Sara Dellasala, Hagop Kantarjian

Blood (2025) 146 (Supplement 1): 5565.

https://doi.org/10.1182/blood-2025-5565

Published: 2025

Journal Articles

Luspatercept response predictors in lower-risk myelodysplastic syndrome

Vanthana Bharathi, Ian Bouligny, Emmanuel Almanza, Alex Bataller, Alexandre Bazinet, Wei-Ying Jen, Niranjan Khaire, Koji Sasaki, Danielle Hammond, Courtney DiNardo, Gautam Borthakur, Tapan Kadia, Naval Daver, Ghayas Issa, Musa Yilmaz, Kelly Chien, Guillermo Montalban-Bravo, Guillermo Garcia-Manero

Blood (2025) 146 (Supplement 1): 5648.

https://doi.org/10.1182/blood-2025-5648

Published: 2025

Journal Articles

A phase I/II trial of azacitidine and venetoclax in previously untreated Myelodysplastic Syndromes

Blood (2025) 146 (Supplement 1): 5647.

https://doi.org/10.1182/blood-2025-5647

Published: 2025

Journal Articles

Phase I study of lower dose CPX-351 combined with venetoclax for patients with higher-risk myelodysplastic syndrome or chronic myelomonocytic leukemia after hypomethylating agents failure

Roberta S. Azevedo, Guillermo Garcia-Manero, Elias Jabbour, Danielle Hammond, Kelly Chien, Tapan Kadia, Steven Kornblau, Farhad Ravandi, Gautam Borthakur, Naveen Pemmaraju, Hyunsoo Hwang, Xuelin Huang, Heather Schneider, Meghan Meyer, Guillermo Montalban-Bravo

Blood (2025) 146 (Supplement 1): 5645.

https://doi.org/10.1182/blood-2025-5645

Published: 2025

Journal Articles

Evaluating the impact of stem cell transplantation in myelodysplastic syndrome using machine learning and comparative modeling

Ziyi Li, Kelly Chien, Yue Lyu, Koji Sasaki, Ian Bouligny, Yue Wei, Guillermo Montalban-Bravo, Sanam Loghavi, Alex Bataller, Uday Popat, Hagop Kantarjian, Alexandre Bazinet, Guillermo Garcia-Manero

Blood (2025) 146 (Supplement 1): 5644.

https://doi.org/10.1182/blood-2025-5644

Published: 2025

Journal Articles

Complex cytogenetics in myeloid malignancies: A deconstruction analysis redefining complex karyotypes

Alex Bataller, Alexandre Bazinet, Guillermo Montalban-Bravo, Kelly Chien, Danielle Hammond, Ian Bouligny, Jayastu Senapati, Koji Sasaki, Ghayas Issa, Nicholas Short, Tapan Kadia, Rashmi Kanagal-Shamanna, Sanam Loghavi, Guilin Tang, Elias Jabbour, Farhad Ravandi, Hagop Kantarjian, Guillermo Garcia-Manero

Blood (2025) 146 (Supplement 1): 5641.

https://doi.org/10.1182/blood-2025-5641

Published: 2025

Journal Articles

A first-in-human study of stx-0712, a CCR2+ cytotoxicity targeting chimera (CyTAC™) in patients with chronic myelomonocytic leukemia (CMML) and Acute Myeloid Leukemia (AML)

Guillermo Montalban-Bravo, Courtney DiNardo, Peter Greenberg, Richard Stone, Eric Padron, David Sallman, Curtis Lachowiez, Jonathan Abbas, Abhishek Mangaonkar, Mrinal Patnaik, Marissa Timothy, Alonzo Martinez, Ewelina Morawa, Brandon Turunen, Philip Vickers, Sergio Santillana

Blood (2025) 146 (Supplement 1): 3874.

https://doi.org/10.1182/blood-2025-3874

Published: 2025

Journal Articles

Outcomes of clinical trial screening in patients with Myelodysplastic Syndromes and chronic myelomonocytic leukemia

Blood (2025) 146 (Supplement 1): 3867.

https://doi.org/10.1182/blood-2025-3867

Published: 2025

Journal Articles

RUNX1 mutations define a high-risk biological subset of chronic myelomonocytic leukemia and cooperate with ASXL1 mutations to drive leukemic transformation

Blood (2025) 146 (Supplement 1): 3857.

https://doi.org/10.1182/blood-2025-3857

Published: 2025

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Outcomes of hypomethylating agent failure in patients with myelodysplastic syndromes

Characteristics, genomic landscape, and prognostic impact of trisomy 8 on contemporary outcomes in patients with newly diagnosed Acute Myeloid Leukemia (AML)

Impact of NPM1 co-mutation on outcomes in RAS-mutated Acute Myeloid Leukemia

Prognostic and therapeutic impact of FLT3 mutations and allelic burden in myelodysplastic syndromes and chronic myelomonocytic leukemia: Results from a multicenter cohort study

Clinical and biological correlates of blast-transformed chronic myelomonocytic leukemia (CMML): A multicenter study of 493 paired cases at chronic phase and at blast transformation

Clinical characteristics, demographics, and survival outcomes in newly diagnosed CUX1-mutated Acute Myeloid Leukemia

A Phase II study of azacitidine, venetoclax, and gilteritinib for newly diagnosed adverse risk FLT3-wild type acute myeloid leukemia

Clinical outcomes of patients with IDH1/IDH2-mutated clonal hematopoiesis: A single-center retrospective study

A phase I study of the T-cell receptor-like antibody Hu8F4 in pts with advanced myeloid neoplasms

Cladribine-based low-intensity therapy is safe and effective in patients with newly diagnosed Acute Myeloid Leukemia (AML) and renal impairment

Area deprivation index does not influence survival in patients with lower-risk myelodysplastic syndromes at a major cancer center

Asciminib for newly diagnosed chronic myeloid leukemia: Results from A phase II trial

Luspatercept response predictors in lower-risk myelodysplastic syndrome

A phase I/II trial of azacitidine and venetoclax in previously untreated Myelodysplastic Syndromes

Phase I study of lower dose CPX-351 combined with venetoclax for patients with higher-risk myelodysplastic syndrome or chronic myelomonocytic leukemia after hypomethylating agents failure

Evaluating the impact of stem cell transplantation in myelodysplastic syndrome using machine learning and comparative modeling

Complex cytogenetics in myeloid malignancies: A deconstruction analysis redefining complex karyotypes

A first-in-human study of stx-0712, a CCR2+ cytotoxicity targeting chimera (CyTAC™) in patients with chronic myelomonocytic leukemia (CMML) and Acute Myeloid Leukemia (AML)

Outcomes of clinical trial screening in patients with Myelodysplastic Syndromes and chronic myelomonocytic leukemia

RUNX1 mutations define a high-risk biological subset of chronic myelomonocytic leukemia and cooperate with ASXL1 mutations to drive leukemic transformation

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only